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Abstract
Background: Antiretroviral therapy (ART) has been scaled-up rapidly in Africa. Programme reports typically focus on loss to
follow-up and mortality among patients receiving ART. However, little is known about linkage and retention in care of
individuals prior to starting ART.
Methodology: Data on adult residents from a periurban community in Cape Town were collected at a primary care clinic
and hospital. HIV testing registers, CD4 count results provided by the National Health Laboratory System and ART registers
were linked. A random sample (n=885) was drawn from adults testing HIV positive through antenatal care, sexual
transmitted disease and voluntary testing and counseling services between January 2004 and March 2009. All adults
(n=103) testing HIV positive through TB services during the same time period were also included in the study. Linkage to
HIV care was defined as attending for a CD4 count measurement within 6 months of HIV diagnosis. Linkage to ART care was
defined as initiating ART within 6 months of HIV diagnosis in individuals with a CD4 count #200 cells/ml taken within 6
months of HIV diagnosis.
Findings: Only 62.6% of individuals attended for a CD4 count measurement within 6 months of testing HIV positive.
Individuals testing through sexually transmitted infection services had the best (84.1%) and individuals testing on their own
initiative (53.5%) the worst linkage to HIV care. One third of individuals with timely CD4 counts were eligible for ART and
66.7% of those were successfully linked to ART care. Linkage to ART care was highest among antenatal care clients. Among
individuals not yet eligible for ART only 46.3% had a repeat CD4 count. Linkage to HIV care improved in patients tested in
more recent calendar period.
Conclusion: Linkage to HIV and ART care was low in this poor peri-urban community despite free services available within
close proximity. More efforts are needed to link VCT scale-up to subsequent care.
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Introduction
South Africa is home to one-sixth of the world’s population
living with HIV and has the largest antiretroviral therapy (ART)
programme in the world [1,2]. ART roll out began nationally in
late 2003 and by the middle of 2008, 568,000 adults and children
were receiving ART. This translated into around 40% of eligible
adults receiving ART in 2008 [3], although the latest guidelines
recommend earlier initiation for certain patients, thus increasing
the numbers eligible for ART and widening the treatment gap [4].
In an effort to increase access to prevention and care, South
Africa launched an ambitious national campaign in April 2010
aiming to test 15 million people for HIV and to reach 1.5 million
people with ART by June 2011. Increased HIV testing may
impact on risk behavior in the short-term [5]. However, there is
also a need to ensure that those who need treatment are linked to
the appropriate services while those not eligible for treatment are
monitored and started on ART when appropriate. A study from
Durban, South Africa, reported that almost two-thirds of newly
diagnosed patients accessing care in a semi-private hospital were
lost to care between HIV diagnosis and getting a CD4 count, and
another one in five patients were lost between CD4 testing and
ART initiation [6,7]. Another study from South Africa found that
only 45% of eligible patients started ART in a public sector ART
project in Free State. Mortality and TB incidence in patients
failing to initiate ART was more than 2 times higher compared to
patients initiating ART [8].
The impact of ART on mortality, morbidity, TB incidence
[9,10] and HIV transmission [11] at a population level depends on
ART coverage. ART coverage defined as the number of patients
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e13801receiving ART at a point in time, divided by the number needing
treatment is determined by timely HIV diagnosis and effective
linkage to ART. This study investigates linkage to HIV and ART
care using a random sample of individuals testing HIV positive
either provided-initiated (through antenatal care (ANC), tubercu-
losis (TB), sexually transmitted infection (STI) services) or client-
initiated (through voluntary counseling and testing (VCT) services)
in a peri-urban township in the Western Cape Province in South
Africa. Linkage to care was defined first as attending for a CD4
count measurement within 6 months of a positive HIV test and
second as the proportion of eligible individuals starting ART
within 6 months of their HIV diagnosis.
Methods
Setting
The study was based in a peri-urban township in the greater
area of Cape Town, with a population of approximately 15,000
people and a measured adult HIV prevalence of 23% in 2005
[12]. The community is served by a single public-sector primary
care clinic, which provides outpatient care including ART free of
charge. A nearby hospital (5 km away) provides all secondary care
for the population, including inpatient and antenatal services. The
hospital also provides ART for some HIV-infected individuals
from the community.
HIV testing, CD4 count measurements and ART services
Client-initiated HIV testing services have been available to all
individuals accessing either the local clinic or the hospital since
2001. Clients who tested on their own initiative are referred to as
having tested through VCT services. Provider-initiated testing was
routinely provided to any patient accessing TB services whose HIV
status was unknown. This was extended to all pregnant females
accessing the hospital or clinic in 2002 and patients accessing STI
services in 2007. All testing required signed consent. All CD4 count
tests were free for patients and performed by the centrally located
National Health Laboratory Services (NHLS) in Cape Town.
ART provision at the primary health care clinic and hospital
began in 2004.
Linkage to HIV and ART care
Linkage to HIV care was defined as attending for a CD4 count
measurement within 6 months of HIV diagnosis. We did not
ascertain if individuals actually received their CD4 counts.
Linkage to ART care was defined as initiating ART within 6
months of HIV diagnosis in individuals with a CD4 count #200
cells/ml taken within 6 months of HIV diagnosis. Having a repeat
CD4 count was defined as having had a repeated CD4 count in
individuals not yet eligible for ART (CD4 count .200 cells/ml)
and tested before 2009.
Data collection
We collected data from 3 sources. First, the primary care clinic
and hospital HIV testing registers provided all data on HIV infected,
adult community residents ($18 years) diagnosed between January
2004 and March 2009. Data at the primary health care clinic were
missing for the period from February 2008 to August 2008. For each
test encounter recorded in the registers, we retrieved data on client
identification variables (first name, surname, date of birth, and
medical record number); place of residence; sex; test acceptance; test
result and service. For HIV infected individuals who tested more
than once, the earliest positive HIV test was considered. Second,
data on CD4 counts performed at either the primary care clinic or
the hospital in the period from 2004 to October 2009 were obtained
fromNHLS.ThedateofCD4countwasthedatetheclientprovided
blood. Third, data from residents who initiated ART care at the
primary health care clinic or hospital were obtained from electronic
ART registers at the clinic and hospital.
These three databases were merged on first name, surname,
medical record number and date of birth. In cases where
identifiers did not match completely two researchers (PG and
KK) independently confirmed that records in different databases
were from the same individual. Concordance between the two
researchers was 97%. Cases where the two researchers disagreed
were discussed until consensus was reached. For all subsequent
analysis data was stripped of all personal identifiers.
Ethics
Written informed consent was obtained from all individuals
initiated on ART and screened for ART. Individuals testing for
HIV are routinely entered into the HIV testing register. Informed
consent was not obtained from HIV positive individuals not
linking to care, as this was a retrospective study and individuals
were not actively follow-up. Data collection and analysis was
approved by the University of Cape Town Ethics Committee and
Partners Human Subjects Institutional Review Board and the
London School of Hygiene and Tropical Medicine.
Statistical analysis
A random sample (n=885) of adults testing HIV positive
through ANC, STI and VCT services between January 2004 and
March 2009 was selected for this analysis. All adults testing
positive through TB services were included in this analysis to
ensure an adequate sample size in this group.
All analyses were carried out using Stata version 11 (Stata Corp.
LP, College Station, TX, United States of America). Proportions
were calculated stratified by service. Total proportions were
calculated taking the different sampling proportions into account.
Risk ratios investigating associations between age, sex, calendar
period and timely linkage to HIV care, CD4 count #200 cells/ml
and repeated CD4 counts were estimated for each service. Risk
ratios were calculated using a log binominal model [13].
Results
HIV testing and HIV prevalence
A total of 8515 records of HIV tests were available for adult
members of the community. The majority of individuals tested
through VCT (n=5345, 62.8%) services (Table 1). The overall
HIV prevalence among those tested was 23.5% with the highest
prevalence among patients tested through TB (37.9%) and VCT
services (24.9%) (x
2 test, p,0.01). The median age of individuals
tested was 26 (interquartile range (IQR), 22–32) and 67.9% were
women. HIV prevalence was 21.6% in men and 24.4% in women.
A total of 2002 clients tested HIV positive. Their median age
was 28 years (IQR, 24–33) and the majority were women (70.3%).
The proportion of women testing HIV positive was 100% in ANC,
66.2% in STI, 38.8% in TB and 66.4% in VCT clients. 1330
(66.4%) individuals tested HIV positive through VCT, 332
(16.6%) through ANC, 237 (11.8%) through STI and 103
(5.1%) through TB services.
Linkage to HIV and ART care
Linkage to HIV and ART care was assessed in a random
sample of 47% of individuals testing HIV positive through ANC,
STI and VCT services and 100% of individuals testing through
TB services: 150 tested through ANC, 113 through STI, 662
through VCT and 103 through TB services. Only 62.6% (95%CI
Linkage to HIV and ART Care
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within 6 months of testing HIV positive (Table 2) and 26.3%
(95%CI 23.5–29.0) did not have any recorded CD4 count test.
The proportion of individuals attending for a CD4 count
measurement within 6 months was highest among individuals
tested through ANC (81.3%) and STI (84.1%) services and lowest
among those who learnt of their status via VCT (53.5%) (Table 2).
Among individuals with a CD4 count measurement within 6
months,34.1% (95%CI 30.4–37.7) were eligible forARTaccording
the South African Department of Health criteria (CD4 count #200
cells/ml) at the time of the study (Table 2). Low CD4 counts were
more prevalent among individuals tested through TB (54.9%) and
VCT services (42.6%). In individuals attending for a CD4 count
measurement within 6 months the median time between HIV test
and CD4 count measurement was: 2 days (IQR 2–6) for ANC, 3
days (IQR 2–4) for STI, 3 days (IQR 2–5) for TB and 2 days (IQR
2–4) for VCT clients. Overall 4.3% of clients attended for a CD4
test at the samedayas the HIVtest.The majorityofclients attended
for CD4 count testing within 1 week (84.9%), 14.2% within 8 days
and 3 months and only 0.9% within 3 and 6 months.
In individuals with a delayed first CD4 count measurements, the
mean time between HIV diagnosis and first CD4 count was 490
days (IQR 345–769). Among patients with delayed first CD4
count measurements, 33.2% (95%CI 24.3–42.1) had a CD4 count
#200 cells/ml and 26.2% (95%CI 17.8–34.8)243.2) had a CD4
count of 201–350 cells/ml.
Only 66.7% (95% CI 60.2–73.1) of eligible individuals with a
timely CD4 count accessed ART care within 6 months of HIV
testing (Table 2). Linkage to ART care was highest among
individuals tested through ANC services (72.2%). Among
individuals not yet eligible for ART only 46.3% (95%CI 41.4–
51.1) ever had a repeat CD4 count. Median time between the first
and the second CD4 count was 236 days.
Figure 1 summarizes the number of people tested through
different services and the numbers linking to HIV and ART care
by service using the proportions estimated from the random
sample.
Table 1. Number (%) of individuals who tested for HIV and
who were found to be positive stratified by type of clinical
service.
ANC
service
STI
service
TB
service
VCT
service Total
Tested N (%) 1525 (17.9) 1370 (16.1) 275 (3.2) 5345 (62.8) 8515 (100)
Positives N (%) 332 (16.6) 237 (11.8) 103 (5.1) 1330 (66.4) 2002 (100)
HIV Prevalence 21.8% 17.3% 37.5% 24.9% 23.5%
All HIV testing records available for the period from January 2004 until March
2009 from adult patients were included in this analysis.
ANC=antenatal care, STI=sexual transmitted infections, TB=tuberculosis,
VCT=voluntary counseling and testing.
doi:10.1371/journal.pone.0013801.t001
Table 2. Percentage of individuals linking to HIV care (as defined by attending for a CD4 cell count measurement), distribution of
CD4 count measurements, percentage of patients subsequently initiating ART and percentage of clients non-eligible for ART
returning for a repeat CD4 count.
Variables
ANC (n=150)
%( N )
STI (n=113)
%( N )
TB (n=103)
%( N )
VCT (n=622)
%( N )
Total
%
First CD4 count after HIV test #6 months 81.3 (122) 84.1 (95) 68.9 (71) 53.5 (333) 62.6 (59.6–65.5)
.6 months 2.0 (3) 2.7 (3) 13.6 (14) 14.8 (92) 11.1 (9.2–13.1)
None 16.7 (25) 13.3 (15) 17.5 (18) 31.7 (197) 26.3 (23.5–29.0)
First CD4 count within 6months of HIV test #200 cells/ml 14.8 (18) 22.1 (21) 54.9 (39) 42.3 (141) 34.1 (30.4–37.7)
201–350 cells/ml 24.6 (30) 32.6 (31) 23.9 (17) 23.7 (79) 25.3 (21.8–28.8)
.351 cells/ml 60.7 (74) 45.3 (43) 21.1 (15) 33.9 (113) 40.6 (36.8–44.4)
ART initiation within 6 months of HIV test in
eligible individuals with timely first CD4 count
Yes 72.2 (13) 52.4 (11) 71.8 (28) 67.4 (95) 66.7 (60.2–73.1)
No 27.8 (5) 47.6 (10) 28.2 (11) 32.6 (46) 33.3 (26.9–39.*)
Repeat CD4 count in individuals with a first CD4
count .200 cells/ml
Yes 48.5 (47) 57.6 (38) 34.5 (10) 42.3 (96) 46.3 (41.4–51.1)
No 51.5 (50) 42.4 (28) 65.5 (19) 57.7 (131) 53.7 (48.9–58.6)
ANC=antenatal care, STI=sexual transmitted infections, TB=tuberculosis, VCT=voluntary counseling and testing.
doi:10.1371/journal.pone.0013801.t002
Figure 1. Number of clients testing HIV+, with timely CD4
counts, eligible for ART and initiating ART estimated using
proportions from table 2. ART=antiretroviral therapy, ANC=ante-
natal care, STI=sexual transmitted infections, TB=tuberculosis,
VCT=voluntary counseling and testing.
doi:10.1371/journal.pone.0013801.g001
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repeated CD4 counts
Risk ratios investigating predictors for linkage to HIV care
showed that linkage to care in TB (RR 1.67, 95%CI 1.27–2.21)
and VCT (RR 1.60, 95%CI 1.40–1.84) clients was more likely in
2007–2009 compared to 2004–2006 (table 3). This was not the
case for ANC (RR 0.97) clients who were slightly less likely to link
to HIV care if tested more recently (table 3). Linkage to ART care
could only be assessed in VCT clients due to the small sample size
in the other groups. Neither age (RR 0.85, 95%CI 0.67–1.09) nor
sex (RR 1.03, 95% CI 0.81–1.31) nor year of testing (RR 1.02,
95% CI 0.81–1.30) predicted linkage to HIV care in VCT clients.
The risk of having CD4 count measurement #200 cells/ml was
higher in individuals aged more than 30 years regardless which
service they tested through (table 4). Repeated CD4 counts were
1.3 times more likely in individuals more than 30 years of age, but
this result only reached significance in the VCT clients (RR 1.25,
95% CI 1.00–1.55).
Discussion
This study evaluated the proportion of individuals linking to
HIV care in a public sector service in Cape Town, South Africa.
Only 63% of patients attended for a CD4 count measurement
within 6 months of diagnosis. Although a substantial proportion of
patients had CD4 counts #200 cells/ml (34%) and were therefore
eligible for ART according to South African guidelines [14], only
67% of these started ART within 6 months. Among those who did
have a timely CD4 count but were not yet eligible for ART, only
46% returned for a repeat CD4 count after a median time of 8
months. Individuals testing through ANC services had better
linkage to HIV and ART care and higher CD4 counts at time of
HIV diagnosis compared to individuals accessing the other
services.
HIV is a chronic disease and comprehensive HIV care needs to
be provided within a continuum of care [15]. ART is just one of
the components of HIV care and care of individuals not yet
requiring ART is equally important [16]. The continuum of HIV
care starts when an individual is diagnosed with HIV. ART
eligibility should be assessed when individuals are newly diagnosed
and in regular (6 monthly) intervals thereafter. Individuals not yet
eligible for ART should receive comprehensive HIV care
including cotrimoxazole, isoniazid preventive therapy, screening
for TB and cervical cancer, contraceptive advice, counseling and
social support until they become eligible for ART. Following
initiation of ART individuals needs to be supported within the
same framework to ensure good adherence and retention in care.
We identified a number of important issues in our study. First,
people who tested on their own initiative were least likely to have a
timely CD4 count measurement done, underscoring the need to
ensure that scale up of VCT programmes will be accompanied by
clear plans to ensure that those who test positive go on to receive
appropriate care. Second, almost a third (28%) of eligible patients
with TB did not receive ART despite recommendations in favour
of concomitant treatment since 2003 [17], and ART being
associated with a 64–95% reduction in mortality in such patients
[10,18,19,20]. This underscores the importance of integrating
HIV and TB services [21].
Table 3. Factors associated with linkage to HIV care (attending for a CD4 count measurement within 6 months of HIV diagnosis)
stratified by service.
Variables ANC STI TB VCT
RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI)
Female NA 1 1 1
Male NA 0.93 (0.79–1.09) 1.01 (0.82–1.25) 1.10 (1.01–1.33)
Age,30 years 1111
Age$30 years 0.97 (0.90–1.04) 1.17 (1.01–1.35) 1.07 (0.84–1.35) 1.16 (0.96–1.26)
Tested in 2004–2006 1N A 11
Tested in 2007–2009 0.87 (0.74–0.99) NA 1.67 (1.27–2.21) 1.60 (1.40–1.84)
ANC=antenatal care, STI=sexual transmitted infections, TB=tuberculosis, VCT=voluntary counseling and testing.
NA=not applicaple.
doi:10.1371/journal.pone.0013801.t003
Table 4. Factors associated with having a CD4 count #200 cells/ml within 6 months of HIV diagnosis.
Variables ANC STI Tb VCT
RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI)
Female NA 1 1 1
Male NA 0.82 (0.36–1.86) 0.97 (0.62–1.50) 1.27 (0.99–1.63)
Age,30 years 1111
Age$30 years 2.42 (1.03–5.68) 2.00 (0.92–4.35) 1.10 (0.68–1.78) 1.40 (1.07–1.82)
Tested in 2004–2006 1N A 11
Tested in 2007–2009 1.32 (0.57–3.08) NA 1.18 (0.75–1.85) 0.94 (0.74–1.19)
ANC=antenatal care, STI=sexual transmitted infections, TB=tuberculosis, VCT=voluntary counseling and testing.
doi:10.1371/journal.pone.0013801.t004
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health services efficiently. Only 30% of clients tested for HIV were
men. This is consistent with studies showing that HIV-infected
men are less likely to access treatment [22,23], present with more
advanced stages of HIV disease [24] and have a higher mortality
risk during ART [25,26,27,28,29,30,31,32]. Repeated CD4
counts were less likely in individuals under 30 years of age as
also reported elsewhere[33].
It is important to note that less than half of patients whose first
CD4 count was above the ART eligibility threshold came back for
a repeat test. One way of improving ART uptake, and thus reduce
mortality among patients who are otherwise lost to care, might be
to change the CD4 threshold to 350 cell/ml in line with the latest
World Health Organization recommendations [34].
Our overall finding that 33% of patients eligible for ART were
lost to care is consistent with several reports from elsewhere in
southern Africa. In a programme report from South Africa, only
55% of patients had a CD4 count measurement within 8 weeks of
HIV diagnosis and 81% of eligible patients were on ART at 3
months follow-up [6,7]. Out of 2483 patients eligible for ART in
Uganda 637 (26%) did not start ART; a third of these patients
died before ART initiation and another quarter were alive but not
taking ART [25]. In Mozambique only 57% of patients testing
HIV positive entered HIV care and 31% of patients eligible for
ART started ART within 3 months [35].
In our study only 63% of patients testing positive for HIV
attended for a CD4 count measurement within 6 months. These
outcomes are worse than those recently reported by a public-sector
clinic in Johannesburg where 84.6% of patients who tested positive
for HIV had a CD4 count measurement. The majority of these
patients did not return for their CD4 result within 12 weeks [36].
Data from the same clinic in Johannesburg showed that among
patients not yet eligible for ART only 26% returned for a
scheduled pre-ART medical visit within one year compared to
43% of our patients not yet eligible for ART returning for a repeat
CD4 count [37].
Substantial improvement in linkage to HIV care for TB and
VCT patients was observed in more recent years in this study and
yet this was not accompanied by improvements in linkage to ART.
Failure of linkage to HIV and ART services translates into
incomplete ART coverage at population level, seriously under-
mining the potential for reductions in mortality, morbidity, TB
incidence and HIV transmission.
The study has several strengths and limitations. Strengths
include that the study was conducted in a routine clinical program
where CD4 count testing and ART were provided free. Thus, the
results should be generalisable to similar settings. The study was
conducted over a prolonged period with increasing ART
availability. Among the limitations is the fact that patients might
have been misclassified as failing to link to care if they accessed
care with a service provider other than the primary health care
clinic or hospital. Thus, linkage to care might be underestimated.
However the nearest other ART site is more than 10 km away,
and residents of this poor community are unlikely to have sought
care in such a distant ART site unless they had moved away.
Second, we did not assess if patients who had a CD4 count
measurement actually returned to receive the result. Thirdly, we
did not investigate reasons for not linking to care. Studies that have
ascertained outcomes among patients lost to care have reported
that up to a third of patients who failed to initiate ART had died
[7,8,25]. Time cut-offs for linkage to care for both timely CD4
count and ART initiation are somewhat arbitrary. When no time
cut-offs were used 75.3% (95% CI 70.3–80.3) of eligible
individuals who had a CD4 count at some point during the study
period eventually initiated ART.
In conclusion, while considerable attention has been paid to loss
to follow-up and mortality among patients receiving ART
[32,38,39,40], data on losses at earlier stages of the care pathway
are scarce. As our study shows, a focus only on outcomes of those
patients fortunate enough to initiate treatment fails to account for
a substantial number of patients who are eligible for ART but do
not receive it or not yet eligible but fail to reappear. Pre-ART
defaulting should be encouraged in programme reporting.
Programme adaptation to ensure retention in care between testing
and ART should consider point of care CD4 count testing at time
of HIV diagnosis as well as provision of integrated TB and HIV.
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